From: Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study
Time | Risk factor | RR | p-value |
---|---|---|---|
First six months period day 0–182 since first R dose | Nadir ≥0.13 ×109 /L | 1.00 |  |
Nadir <0.13 Ă—109 /L | 1.89 (1.00-3.60) | 0.051 | |
HIV neg. | 1.00 | Â | |
HIV pos. | 2.92 (1.11-7.65) | 0.030 | |
no GVHD | 1.00 | Â | |
GVHD | 1.49 (0.52-4.27) | 0.453 | |
Indolent lymphoma | 1.00 | Â | |
Aggressive lymphoma | 2.76 (1.34-5.670 | 0.006 | |
Non-CD20 malignancy | 1.56 (0.56-4.33) | 0.394 | |
Second six months period day 183–364 since first R dose | Nadir ≥0.13 ×109 /L | 1.00 |  |
Nadir <0.13 Ă—109 /L | 2.68 (1.19-6.04) | 0.017 | |
HIV neg. | 1.00 | Â | |
HIV pos. | 1.21 (0.27-5.38) | 0.798 | |
no GVHD | 1.00 | Â | |
GVHD | 7.22 (2.38-21.92) | <0.001 | |
Indolent lymphoma | 1.00 | Â | |
Aggressive lymphoma | 1.21 (0.48-3.02) | 0.687 | |
Non-CD20 malignancy | 1.57 (0.49-4.98) | 0.447 | |
Third six months period day 364–546 since first R dose | Nadir ≥0.13 ×109 /L | 1.00 |  |
Nadir <0.13 Ă—109 /L | 2.54 (1.07-6.02) | 0.034 | |
HIV neg. | 1.00 | Â | |
HIV pos. | 1.49 (0.33-6.67) | 0.601 | |
no GVHD | 1.00 | Â | |
GVHD | 3.65 (1.11-12.04) | 0.034 | |
Indolent lymphoma | 1.00 | Â | |
Aggressive lymphoma | 1.53 (0.60-3.91) | 0.371 | |
Non-CD20 malignancy | 0.93 (0.25-3.42) | 0.908 |